Private equity firm RA Capital Management led a $98m Series C funding round in Kinnate Biopharma, a biopharmaceutical company. The round saw participation from additional new investors, including Viking Global Investors; Venrock Healthcare Capital Partners; Fidelity Management & Research Company, LLC; Janus Henderson Investors; Surveyor Capital; Boxer Capital; Logos Capital; and an investment fund associated with SVB Leerink. Existing investors Foresite Capital, OrbiMed, Nextech Invest, and Vida Ventures also participated in the round. “In just over two years, Kinnate has built a proprietary pipeline of kinase inhibitors from the ground up, and this significant financing positions us to advance at least one of our lead product candidates into clinical development in the first half of next year,” Nima Farzan, Kinnate CEO.